Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

The ATM-BID pathway regulates quiescence and survival of haematopoietic stem cells.

Maryanovich M, Oberkovitz G, Niv H, Vorobiyov L, Zaltsman Y, Brenner O, Lapidot T, Jung S, Gross A.

Nat Cell Biol. 2012 Mar 25;14(5):535-41. doi: 10.1038/ncb2468.

PMID:
22446738
2.

A novel peptide agonist of formyl-peptide receptor-like 1 (ALX) displays anti-inflammatory and cardioprotective effects.

Hecht I, Rong J, Sampaio AL, Hermesh C, Rutledge C, Shemesh R, Toporik A, Beiman M, Dassa L, Niv H, Cojocaru G, Zauberman A, Rotman G, Perretti M, Vinten-Johansen J, Cohen Y.

J Pharmacol Exp Ther. 2009 Feb;328(2):426-34. doi: 10.1124/jpet.108.145821. Epub 2008 Nov 20.

PMID:
19023040
3.

Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells.

Beiner ME, Niv H, Haklai R, Elad-Sfadia G, Kloog Y, Ben-Baruch G.

Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:200-6.

PMID:
16515591
4.

Proapoptotic BID is an ATM effector in the DNA-damage response.

Kamer I, Sarig R, Zaltsman Y, Niv H, Oberkovitz G, Regev L, Haimovich G, Lerenthal Y, Marcellus RC, Gross A.

Cell. 2005 Aug 26;122(4):593-603.

5.

Mitochondrial carrier homolog 2 is a target of tBID in cells signaled to die by tumor necrosis factor alpha.

Grinberg M, Schwarz M, Zaltsman Y, Eini T, Niv H, Pietrokovski S, Gross A.

Mol Cell Biol. 2005 Jun;25(11):4579-90.

6.

Galectin-1(L11A) predicted from a computed galectin-1 farnesyl-binding pocket selectively inhibits Ras-GTP.

Rotblat B, Niv H, André S, Kaltner H, Gabius HJ, Kloog Y.

Cancer Res. 2004 May 1;64(9):3112-8.

7.

Rac2 regulation of phospholipase C-beta 2 activity and mode of membrane interactions in intact cells.

Illenberger D, Walliser C, Strobel J, Gutman O, Niv H, Gaidzik V, Kloog Y, Gierschik P, Henis YI.

J Biol Chem. 2003 Mar 7;278(10):8645-52. Epub 2002 Dec 30.

8.

Activated K-Ras and H-Ras display different interactions with saturable nonraft sites at the surface of live cells.

Niv H, Gutman O, Kloog Y, Henis YI.

J Cell Biol. 2002 May 27;157(5):865-72. Epub 2002 May 20.

9.

Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS).

Katzav A, Kloog Y, Korczyn AD, Niv H, Karussis DM, Wang N, Rabinowitz R, Blank M, Shoenfeld Y, Chapman J.

Clin Exp Immunol. 2001 Dec;126(3):570-7.

10.

The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis.

Karussis D, Abramsky O, Grigoriadis N, Chapman J, Mizrachi-Koll R, Niv H, Kloog Y.

J Neuroimmunol. 2001 Nov 1;120(1-2):1-9.

PMID:
11694313
11.
12.
13.

Supplemental Content

Support Center